Skip to main content

Belite Bio, Inc

corporate_fare Company Profile

Belite Bio, Inc

BLTE·NASDAQ·Life Sciences·CIK 0001889109

BELITE BIO, INC is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics for degenerative retinal diseases with significant unmet medical needs. The company's primary focus areas are Geographic Atrophy (GA), the late atrophic ("dry") form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). Both GA and STGD1 lead to progressive vision loss and permanent blindness in almost all cases. BELITE BIO's lead product candidate is tinlarebant (also known as LBS-008). Tinlarebant is an orally administered, once-a-day tablet designed for early intervention to maintain the health and integrity of retinal tissues in STGD1 and GA patients. Currently, there are no FDA-approved treatments for STGD1 and no approved orally administered treatments for GA. Tinlarebant aims to address this unmet medical need. The drug works by reducing the accumulation of bisretinoid toxins, which are implicated in the progression of retinal disease in both STGD1 and GA. Bisretinoids are derived from circulating retinol, and tinlarebant, developed from the company's RBP4 intellectual property portfolio, is a potent and reversible RBP4 antagonist. By antagonizing serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol delivery to the eye, tinlarebant reduces retinol entry into the visual cycle, thereby decreasing bisretinoid toxin formation and preserving retinal health. In addition to tinlarebant, BELITE BIO's drug development pipeline includes LBS-009, a small molecule, orally administered compound. LBS-009 is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Belite Bio, Inc (NASDAQ:BLTE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BLTE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for BLTE spans 6-K, 144, 20-F.

Recent high-impact activity:

  • FDA Extends Tinlarebant NDA Review by Three Months; PDUFA Date Now May 12, 2027
  • FDA Pushes Tinlarebant Decision Back Three Months to May 2027
  • Belite Bio Q3: FDA Skips Adcom for Tinlarebant NDA, PDUFA Set for February 12, 2027
  • Belite Bio Submits NDA in Japan for Tinlarebant Under Sakigake Designation
  • Q2 2026 Results: Net Loss Widens to $28.4M, Yet Cash Position Remains Strong at $780M

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$77.61M
Diluted EPS
-$2.31
Op. Cash Flow
-$36.99M
Free Cash Flow
-$37.06M
Operating Income
-$84.21M
Cash & Equivalents
$352.93M
Debt / Equity
0.00×
Shares Outstanding
39.34M sh
Source: 20-F · filed 2026-03-31 · accession 0001104659-26-037374

Short Interest & Short Volume

9.96 days to cover

FINRA reported short interest of 1,380,466 shares in BLTE as of the October 30, 2026 settlement, a 8.9% increase from the prior period — about 10.0 days to cover at its recent average daily volume. On November 20, 2026, 65.7% of BLTE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,380,466 shares as of October 30, 2026
Change vs prior period▲ 8.9%
Days to cover9.96 at avg daily volume of 138,665
Daily short volume (FINRA facilities)65.7% of 486,950 shares on November 20, 2026
5-day average short volume63.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BLTE, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.

1 recent capital raise

Warrant Shares Re-Registered · Minimal Proceeds at Stake

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

BLTE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with B →
$129 -14.58% today
52-week range · as of 2026-11-20 $105.88 – $200
Market cap
$5.17B
Volume
1M (5.1× avg)
3-mo avg 203.3K
Live data · 2026-11-22 08:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BLTE - Latest Insights

BLTE
Nov 20, 2026, 8:05 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $146.06
Real-time Price: $129.00 info
Change: -$17.06 (-12%) info
Market Cap: $5.173B info
BLTE
Nov 20, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $146.06
Real-time Price: $129.00 info
Change: -$17.06 (-12%) info
Market Cap: $5.173B info
BLTE
Nov 12, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $156.00
Real-time Price: $129.00 info
Change: -$27.00 (-17%) info
Market Cap: $5.173B info
BLTE
Sep 08, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $193.61
Real-time Price: $129.00 info
Change: -$64.61 (-33%) info
Market Cap: $5.173B info
BLTE
Aug 12, 2026, 9:50 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $178.94
Real-time Price: $129.00 info
Change: -$49.94 (-28%) info
Market Cap: $5.173B info
BLTE
Aug 12, 2026, 9:45 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $178.94
Real-time Price: $129.00 info
Change: -$49.94 (-28%) info
Market Cap: $5.173B info
BLTE
Aug 12, 2026, 5:13 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $178.94
Real-time Price: $129.00 info
Change: -$49.94 (-28%) info
Market Cap: $5.173B info
BLTE
Aug 11, 2026, 4:49 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $180.00
Real-time Price: $129.00 info
Change: -$51.00 (-28%) info
Market Cap: $5.173B info
BLTE
Aug 11, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $180.00
Real-time Price: $129.00 info
Change: -$51.00 (-28%) info
Market Cap: $5.173B info
BLTE
Jul 20, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $150.08
Real-time Price: $129.00 info
Change: -$21.08 (-14%) info
Market Cap: $5.173B info
BLTE
Jun 12, 2026, 9:42 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $138.16
Real-time Price: $129.00 info
Change: -$9.16 (-7%) info
Market Cap: $5.173B info
BLTE
May 20, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $139.70
Real-time Price: $129.00 info
Change: -$10.70 (-8%) info
Market Cap: $5.173B info
BLTE
May 20, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $139.70
Real-time Price: $129.00 info
Change: -$10.70 (-8%) info
Market Cap: $5.173B info
BLTE
Apr 21, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $165.23
Real-time Price: $129.00 info
Change: -$36.23 (-22%) info
Market Cap: $5.173B info
BLTE
Apr 09, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $181.17
Real-time Price: $129.00 info
Change: -$52.17 (-29%) info
Market Cap: $5.173B info
BLTE
Mar 31, 2026, 8:00 AM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $149.18
Real-time Price: $129.00 info
Change: -$20.18 (-14%) info
Market Cap: $5.173B info
BLTE
Mar 02, 2026, 6:13 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $190.30
Real-time Price: $129.00 info
Change: -$61.30 (-32%) info
Market Cap: $5.173B info
BLTE
Mar 02, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $190.30
Real-time Price: $129.00 info
Change: -$61.30 (-32%) info
Market Cap: $5.173B info
BLTE
Mar 02, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $190.30
Real-time Price: $129.00 info
Change: -$61.30 (-32%) info
Market Cap: $5.173B info
BLTE
Jan 27, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $165.79
Real-time Price: $129.00 info
Change: -$36.79 (-22%) info
Market Cap: $5.173B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets